ESLA
Estrella Immunopharma, Inc.
Going-concern doubt
— flagged May 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, management has determined that there is a substantial doubt about its ability to continue as a going concern.”View the 10-Q filed May 18, 2026
Company with tickers: ESLA, ESLAW
CIK
1844417
CUSIP
297584104
Shares Outstanding
43,034,228
Website
https://www.estrellabio.com
Investor Relations
https://www.estrellabio.com/investors
13F Activity (30d)
1 filings
1 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $2,292,064 | USD | 2026-03-31 | 10-Q | 2026-05-18 |
| Research & Development | $1,400,275 | USD | 2026-03-31 | 10-Q | 2026-05-18 |
| Operating Income | $-2,292,064 | USD | 2026-03-31 | 10-Q | 2026-05-18 |
| Net Income | $-2,292,064 | USD | 2026-03-31 | 10-Q | 2026-05-18 |
| EPS (Basic) | $-0.05 | USD/shares | 2026-03-31 | 10-Q | 2026-05-18 |
| EPS (Diluted) | $-0.05 | USD/shares | 2026-03-31 | 10-Q | 2026-05-18 |